S55746 | BCL201 | Bcl-2 Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / / S55746

S55746 {[allProObj[0].p_purity_real_show]}

货号：A887253 同义名： BCL201

S55746 is a potent and selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities.

S55746 化学结构
CAS号：1448584-12-0

S55746 3D分子结构
CAS号：1448584-12-0

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

S55746 纯度/质量文件产品仅供科研

货号：A887253 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]; • JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]; • BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]; • J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]; • PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]; 更多 >

Bcl-2 亚型比较

产品名称	Bax ↓ ↑	Bcl-2 ↓ ↑	Bcl-B ↓ ↑	Bcl-w ↓ ↑	Bcl-xL ↓ ↑	Bfl-1 ↓ ↑	Mcl-1 ↓ ↑	其他靶点	纯度
BTSA1	✔								99%+
HA14-1		+ Bcl-2, IC50: 9 μM							98%
Venetoclax		++++ Bcl-2, Ki: <0.01 nM							99%
Navitoclax									99%+
Obatoclax Mesylate		+++ Bcl-2, Ki: 0.22 μM							98%
ABT-737		+++ Bcl-2, EC50: 30.3 nM	+ Bcl-B, EC50: 1.82 μM	+++ Bcl-w, EC50: 197.8 nM	+++ Bcl-xL, EC50: 78.7 nM				99%+
Gambogic Acid		+ Bfl-1, IC50: 1.06 μM Bcl-2, IC50: 1.21 μM	++ Bcl-B, IC50: 0.66 μM	++++ Bcl-w, IC50: 0.02 μM	+ Bcl-xL, IC50: 1.47 μM	+ Bfl-1, IC50: 1.06 μM	++ Mcl-1, IC50: 0.79 μM	Caspase	99% HPLC
BH3I-1					+ BH3-Bcl-xL interaction, Ki: 2.4 μM				98%
A-1331852					++++ Bcl-xL, Ki: <0.01 nM				99%+
A-1210477							++++ MCL-1, IC50: 26.2 nM		99%+
Maritoclax							✔		97%
TW-37		+++ Bcl-2, Ki: 0.29 μM			+ Bcl-xL, Ki: 1.11 μM		+++ Mcl-1, Ki: 0.26 μM		98%
UMI-77							++ Mcl-1, Ki: 490 nM		97%
(R)-(-)-Gossypol acetic acid		++ Bcl-2, Ki: 0.32 μM			++ Bcl-xL, Ki: 0.48 μM		+++ Mcl-1, Ki: 0.18 μM		98%
Sabutoclax		++ Bfl-1, IC50: 0.62 μM Bcl-2, IC50: 0.32 μM			++ Bcl-xL, IC50: 0.31 μM	++ Bfl-1, IC50: 0.62 μM	+++ Mcl-1, IC50: 0.20 μM		98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

S55746 生物活性

描述	S55746 is a potent, orally active and selective BCL-2 inhibitor with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 is effective in selectively inducing cell death through inhibition of BCL-2 in a BAX/BAK-dependent manner at a concentration of 1 μM^[1].

S55746 动物研究

Animal study

S55746 is a highly potent and well-tolerated. Administered orally at doses of 20-100 mg/kg, S55746 inhibits xenograft growth in a time- and dose-dependent manner in RS4;11 and Toledo models^[1].

S55746 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02603445	Follicular Lymphoma, Mantle Ce... 展开 >>ll Lymphoma 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Novartis Investigative Site New York, New York, United States, 10017 United States, Texas Novartis Investigative Site Houston, Texas, United States, 77030 Austria Novartis Investigative Site Salzburg, Austria, 5020 France Novartis Investigative Site Pierre-Benite Cedex, France, 69495 Novartis Investigative Site Toulouse Cedex 9, France, 31059 Germany Novartis Investigative Site Freiburg, Germany, 79106 Novartis Investigative Site Mainz, Germany, 55131 收起 <<
NCT02920697	Chronic Lymphocytic Leukaemia ... 展开 >>(CLL) B-Cell Non-Hodgkin Lymphoma (NHL) Multiple Myeloma (MM) 收起 <<	Phase 1	Completed	-	Australia ... 展开 >> The Alfred Hospital Malignant Haematology & Stem Cell Transplantation Services Melbourne, Australia, 3004 France Hopital Claude Huriez Lille, France CHU de Nantes Nantes, France Centre hospitalier Lyon Sud Pierre-Bénite, France Gustave Roussy Villejuif, France Germany Universitätsklinikum Carl Gustav Carus Dresden, Germany Städtisches Klinikum Schwabing Munich, Germany Universitätsklinikum Ulm Ulm, Germany Hungary National Oncology Institute Budapest, Hungary CRU Hungary Kft Miskolc, Hungary Korea, Republic of Severance Hospital Seoul, Korea, Republic of St. Mary's Hospital Seoul, Korea, Republic of Poland Warsaw Institute of Oncology Warsaw, Poland Warsaw Medical University Warsaw, Poland Singapore National Cancer Center (NCC) Singapore, Singapore National University Cancer Institute Singapore Singapore, Singapore United Kingdom University College London Hospitals London, United Kingdom Freeman Hospital Newcastle, United Kingdom 收起 <<

S55746 参考文献

[1]Casara P, et al. S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget. 2018 Apr 13;9(28):20075-20088.

S55746 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.41mL

0.28mL

0.14mL

7.03mL

1.41mL

0.70mL

14.07mL

2.81mL

1.41mL

S55746 技术信息

CAS号	1448584-12-0
分子式	C₄₃H₄₂N₄O₆
分子量	710.817

别名	BCL201
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,2-8°C

溶解度

DMSO: 50 mg/mL(70.34 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02603445	Follicular Lymphoma, Mantle Ce... 展开 >>ll Lymphoma 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Novartis Investigative Site New York, New York, United States, 10017 United States, Texas Novartis Investigative Site Houston, Texas, United States, 77030 Austria Novartis Investigative Site Salzburg, Austria, 5020 France Novartis Investigative Site Pierre-Benite Cedex, France, 69495 Novartis Investigative Site Toulouse Cedex 9, France, 31059 Germany Novartis Investigative Site Freiburg, Germany, 79106 Novartis Investigative Site Mainz, Germany, 55131 收起 <<
NCT02920697	Chronic Lymphocytic Leukaemia ... 展开 >>(CLL) B-Cell Non-Hodgkin Lymphoma (NHL) Multiple Myeloma (MM) 收起 <<	Phase 1	Completed	-	Australia ... 展开 >> The Alfred Hospital Malignant Haematology & Stem Cell Transplantation Services Melbourne, Australia, 3004 France Hopital Claude Huriez Lille, France CHU de Nantes Nantes, France Centre hospitalier Lyon Sud Pierre-Bénite, France Gustave Roussy Villejuif, France Germany Universitätsklinikum Carl Gustav Carus Dresden, Germany Städtisches Klinikum Schwabing Munich, Germany Universitätsklinikum Ulm Ulm, Germany Hungary National Oncology Institute Budapest, Hungary CRU Hungary Kft Miskolc, Hungary Korea, Republic of Severance Hospital Seoul, Korea, Republic of St. Mary's Hospital Seoul, Korea, Republic of Poland Warsaw Institute of Oncology Warsaw, Poland Warsaw Medical University Warsaw, Poland Singapore National Cancer Center (NCC) Singapore, Singapore National University Cancer Institute Singapore Singapore, Singapore United Kingdom University College London Hospitals London, United Kingdom Freeman Hospital Newcastle, United Kingdom 收起 <<

S55746 {[allProObj[0].p_purity_real_show]}

S55746 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

S55746 质控信息

S55746 生物活性

S55746 动物研究

S55746 临床研究

S55746 参考文献

S55746 实验方案

S55746 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

S55746 {[allProObj[0].p_purity_real_show]}

S55746 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

S55746 质控信息

S55746 生物活性

S55746 动物研究

S55746 临床研究

S55746 参考文献

S55746 实验方案

S55746 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

S55746 纯度/质量文件产品仅供科研